Nav: Home

Sorting out HIV

May 25, 2017

Around 1% of patients with HIV - known as elite controllers - are able to survive without antiviral treatment, because their immune systems produce certain kinds of HIV-specific antibodies: proteins that recognise features on the surface of the virus and bind to them, making the virus inactive. The challenge in developing an HIV vaccine is to identify specific features in the proteins on the virus's surface which are recognised by the immune system and elicit a response similar to that seen in elite controllers.

A widely used technique for studying proteins on the surfaces of cells - which is sometimes also used with viruses - is fluorescence-activated cell sorting (FACS). You take a sample of cells and add fluorescent antibodies that bind to the surface proteins you're interested in. Cells with proteins that are recognised by the antibodies will become fluorescent, while cells lacking such proteins will not. You can then measure the fluorescence of each cell individually, sending the fluorescent cells into one container for further study, and the non-fluorescent cells into another. This works well for studying cells, which have hundreds of surface proteins for the antibodies to bind to, producing a strong fluorescence signal. FACS can also be used to sort large viruses such as the Ebola virus, but for studying smaller viruses with fewer surface proteins - like HIV - FACS is not sensitive enough. Now researchers at EMBL, ESPCI Paris, and the International AIDS Vaccine Initiative have developed a new technique for rapidly sorting HIV viruses, which could lead to more rapid development of a vaccine for HIV, as they report in Cell Chemical Biology. Study author Christoph Merten explains.

What did you do?

We developed a system that enables us to analyse and sort HIV at a rate of hundreds of viruses per second, separating the viruses according to whether or not their surface proteins have features recognised by specific antibodies. Instead of using fluorescent antibodies that would bind directly to the viral proteins - producing only a weak signal - we took the ordinary, non-fluorescent antibodies and attached them to an enzyme called alkaline phosphatase (AP). We then enclosed the viruses individually in droplets of liquid, along with a chemical that becomes fluorescent when acted on by AP. The antibodies bind to the viral proteins, and the attached AP enzymes produce many fluorescent molecules which remain inside the liquid droplet, creating a strong fluorescence signal. If the virus's proteins don't have the right features, the antibodies with their AP enzymes will not bind and no fluorescence is produced. We can therefore study individual viruses, sorting them with high accuracy according to whether they show features that could be exploited in developing a vaccine against HIV.

Ours is a microfluidic system - in other words, it uses technology designed for manipulating extremely small quantities of liquid. The whole system is contained on a microfluidic 'chip' - a palm-sized device consisting of microscopic networks of channels for liquid to flow through. These channels are just a few hundredths of a millimetre across, and each droplet in our experiments is around 30 billionths of a millilitre. Microfluidic chips offer particular advantages when working with pathogens like HIV, since they're completely sealed and therefore very safe to use. Typical FACS systems can produce airborne droplets, so much more stringent containment measures are required when working with harmful bacteria and viruses.

Why does it matter?

Our method makes it possible to analyse and sort HIV viruses in quantities and at speeds that have not been possible before. This enables us to rapidly test millions of viral variants, which should significantly speed up the process of vaccine development.

In our experiments each droplet contained a virus and antibodies, but it should also be possible to add a cell to the droplet and study whether the antibodies can stop the virus from entering the cell. That's not possible with FACS, so it opens up many possibilities for future research.
-end-


European Molecular Biology Laboratory

Related Immune System Articles:

Using the immune system as a defence against cancer
Research published today in the British Journal of Cancer has found that a naturally occurring molecule and a component of the immune system that can successfully target and kill cancer cells, can also encourage immunity against cancer resurgence.
First impressions go a long way in the immune system
An algorithm that predicts the immune response to a pathogen could lead to early diagnosis for such diseases as tuberculosis
Filming how our immune system kill bacteria
To kill bacteria in the blood, our immune system relies on nanomachines that can open deadly holes in their targets.
Putting the break on our immune system's response
Researchers have discovered how a tiny molecule known as miR-132 acts as a 'handbrake' on our immune system -- helping us fight infection.
Decoding the human immune system
For the first time ever, researchers are comprehensively sequencing the human immune system, which is billions of times larger than the human genome.
More Immune System News and Immune System Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...